News Merck KGaA's ATR cancer drug cleared for further trials afte... Merck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in a phase 1 study.
Oncology Breaking barriers to CAR T-cell therapy: The vision for expa... Live from ASCO 2025: Prof. Dr Jason Westin discusses CAR-T Vision, patient access, and the push to expand therapy reach in rare blood cancers.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.